R&G PharmaStudies Co., Ltd. Class A

R&G PharmaStudies Co., Ltd. Class A

SSZSE:301333
51.59
CNY
-0.73
(-1.40%)
1.25EPS
54.63P/E
6.44BMarket Cap
Mar 29Next Earn

Total Valuation

CNY

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A carries a market capitalization of 6.44B, placing it among publicly traded companies globally. Its enterprise value stands at 4.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.44B
Enterprise Value4.83B

Important Dates

R&G PharmaStudies Co., Ltd. Class A's next confirmed earnings release is scheduled for March 29, 2027.

Earnings Date3/29/2027

Share Statistics

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A has 96.58M shares outstanding.

Shares Outstanding96.58M

Valuation Ratios

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 54.63. The price-to-sales ratio is 6.65, and the price-to-book ratio stands at 3.23.

PE Ratio54.63
PS Ratio6.65
PB Ratio3.23
P/TBV Ratio3.39

Enterprise Valuation

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A trades at an EV/EBITDA multiple of 36.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.91 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.83B versus a market cap of 6.44B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.05
EV / EBITDA36.91
EV / EBIT36.91

Financial Position

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A maintains a current ratio of 5.64, meaning it holds 5.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.50, indicating elevated leverage, while an interest coverage ratio of 59.22 demonstrates strong ability to service its debt obligations.

Current Ratio5.64
Quick Ratio4.33
Debt / Equity2.50
Debt / EBITDA0.38
Interest Coverage59.22

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, R&G PharmaStudies Co., Ltd. Class A posted a return on equity (ROE) of 6.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.07 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.93, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.81, useful for judging operating efficiency across full business cycles. The company generates approximately 361,975.35 in revenue per employee across its workforce of 2,645.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.07 indicates how many times R&G PharmaStudies Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.00
Return on Assets (ROA)4.93
Return on Invested Capital (ROIC)6.07
Return on Capital Employed (ROCE)5.81
Revenue Per Employee361,975.35
Employee Count2,645.00
Inventory Turnover11.07

Taxes

CNY

Over the twelve months ended September 30, 2026, R&G PharmaStudies Co., Ltd. Class A recorded 9.19M in income tax expense. That works out to an effective tax rate of 7.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 128.28M, leaving 116.51M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax9.19M
Effective Tax Rate7.16

Stock Price Statistics

CNY

As of the close on November 17, 2026, R&G PharmaStudies Co., Ltd. Class A's stock has declined approximately 14.84% over the past 52 weeks. The 50-day moving average sits at 58.15, while the 200-day moving average is 59.51.

52-Week Price Change-14.84%
50-Day Moving Average58.15
200-Day Moving Average59.51

Income Statement

CNY

Over the twelve months ended September 30, 2026, R&G PharmaStudies Co., Ltd. Class A generated 957.42M in revenue and converted that into 116.51M in net income, yielding earnings per share of 1.25. EBITDA reached 130.98M, while operating income came in at 122.04M.

Revenue957.42M
Gross Profit291.99M
Operating Income122.04M
Pretax Income128.28M
Net Income116.51M
EBITDA130.98M
EBIT130.98M
Earnings Per Share (EPS)1.25

Balance Sheet

CNY

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A holds 1.67B in cash and equivalents against 50.08M in total debt, resulting in a net debt position of -1.31B. Total book value stands at 2.00B, with working capital of 1.78B providing operational flexibility.

Cash & Cash Equivalents1.67B
Total Debt50.08M
Net Debt-1.31B
Equity (Book Value)2.00B
Book Value Per Share20.67
Working Capital1.78B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-15.99M

Margins

Over the twelve months ended September 30, 2026, R&G PharmaStudies Co., Ltd. Class A posted a gross margin of 30.50, reflecting its pricing power and cost economics. The operating margin of 12.75 and net profit margin of 12.17 provide insight into operational efficiency.

Gross Margin30.50
Operating Margin12.75
Pretax Margin13.40
Profit Margin12.17
EBITDA Margin13.68

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, R&G PharmaStudies Co., Ltd. Class A paid dividends of 0.23 per share. The dividend payout ratio of 17.89 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.31, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to R&G PharmaStudies Co., Ltd. Class A shareholders.

Dividend Per Share0.23
Payout Ratio17.89
Shareholder Yield1.31

Stock Splits

R&G PharmaStudies Co., Ltd. Class A's most recent stock split took place on June 29, 2023 with a 5:8 split ratio.

Last Split Date6/29/2023
Split Ratio5:8

Scores

As of September 30, 2026, R&G PharmaStudies Co., Ltd. Class A has an Altman Z-Score of 11.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.37